FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068697939> ?p ?o ?g. }

• W2068697939 endingPage "435" @default.
• W2068697939 startingPage "430" @default.
• W2068697939 abstract "In a case-control study in patients with acute ischemic stroke and extracranial internal carotid artery (eICA) occlusion, thrombolytic treatment was associated with increased mortality. The aim of this cohort study was to assess the efficacy and safety of thrombolysis in patients with eICA occlusion compared to those without eICA occlusion.Consecutive patients treated with intravenous tissue-type plasminogen activator within 4.5 h from symptom onset included in the Safe Implementation of Thrombolysis in Stroke - International Stroke Thrombolysis Registry (SITS-ISTR) in 20 Italian centres were analyzed. Acute carotid occlusion was diagnosed using ultrasound examination, angio-CT scan or angio-MRI. Since the SITS-ISTR database did not plan to report the site of vessel occlusion, each participating center provided the code of the patient with eICA occlusion. Patients were divided into 2 groups, those with and those without eICA occlusion. Main outcome measures were: death, disability (modified Rankin Scale, mRS, 3-6) and any intracranial bleeding at 3 months. Multiple logistic regression analysis was performed to reveal predictors for main outcomes. The following variables of interest were included in the analysis: presence of eICA occlusion, age, gender, diabetes mellitus, hyperlipidemia, atrial fibrillation, congestive heart failure, previous stroke, current smoking, antiplatelet treatment at stroke onset, baseline NIHSS score, baseline blood glucose, cholesterol and blood pressure, history of hypertension and stroke onset to treatment time.A total of 1,761 patients without eICA occlusion and 137 with eICA occlusion were included in the study. At 3 months, 42 patients were lost to follow-up (3 with eICA occlusion). Death occurred in 30 (22.4%) patients with eICA occlusion and in 175 (10.2%) patients without (p < 0.0001). Death or disability at 3 months occurred in 91 of 134 patients with eICA occlusion (67.9%) compared with 654 of 1,722 patients without eICA occlusion (37.9%, p < 0.0001). No or minimal disability at 3 months (mRS 0-1) was reported in 25 (18.7%) patients with eICA occlusion and in 829 (48.2%) patients without (p < 0.0001). Any intracranial bleeding detected by CT or MRI at posttreatment imaging was seen in 16 (11.7%) patients with eICA occlusion and in 314 (17.8%) of those without (p = 0.09). The proportion of symptomatic intracerebral hemorrhage was 5.8% for patients with eICA occlusion and 8.0% for patients without (p = 0.16). At logistic regression analysis, eICA occlusion was associated with mortality (odds ratio, OR 5.7; 95% confidence interval, CI 2.9-11.1) and mortality or disability (OR 5.0; 95% CI 2.9-8.7) at 90 days.This cohort study in patients with acute ischemic stroke treated with thrombolysis showed an association between eICA occlusion and adverse outcome." @default.
• W2068697939 created "2016-06-24" @default.
• W2068697939 creator A5000920255 @default.
• W2068697939 creator A5006918138 @default.
• W2068697939 creator A5008224042 @default.
• W2068697939 creator A5009067298 @default.
• W2068697939 creator A5011252047 @default.
• W2068697939 creator A5014564210 @default.
• W2068697939 creator A5016264225 @default.
• W2068697939 creator A5021210152 @default.
• W2068697939 creator A5021310833 @default.
• W2068697939 creator A5021457180 @default.
• W2068697939 creator A5022472213 @default.
• W2068697939 creator A5022557432 @default.
• W2068697939 creator A5025237260 @default.
• W2068697939 creator A5025574771 @default.
• W2068697939 creator A5026655540 @default.
• W2068697939 creator A5033206744 @default.
• W2068697939 creator A5033735435 @default.
• W2068697939 creator A5034912251 @default.
• W2068697939 creator A5035404137 @default.
• W2068697939 creator A5036154881 @default.
• W2068697939 creator A5040344593 @default.
• W2068697939 creator A5042190940 @default.
• W2068697939 creator A5043756231 @default.
• W2068697939 creator A5046622037 @default.
• W2068697939 creator A5049328868 @default.
• W2068697939 creator A5050506462 @default.
• W2068697939 creator A5052544346 @default.
• W2068697939 creator A5053682062 @default.
• W2068697939 creator A5054783539 @default.
• W2068697939 creator A5054833831 @default.
• W2068697939 creator A5058622059 @default.
• W2068697939 creator A5065952002 @default.
• W2068697939 creator A5070954507 @default.
• W2068697939 creator A5075978521 @default.
• W2068697939 creator A5077537095 @default.
• W2068697939 creator A5083153295 @default.
• W2068697939 creator A5086298713 @default.
• W2068697939 creator A5087139584 @default.
• W2068697939 creator A5088791721 @default.
• W2068697939 creator A5089967868 @default.
• W2068697939 creator A5090064810 @default.
• W2068697939 creator A5090521151 @default.
• W2068697939 creator A5090894073 @default.
• W2068697939 date "2012-01-01" @default.
• W2068697939 modified "2023-09-23" @default.
• W2068697939 title "Intravenous Thrombolysis for Acute Ischemic Stroke Associated to Extracranial Internal Carotid Artery Occlusion: The ICARO-2 Study" @default.
• W2068697939 cites W1968422076 @default.
• W2068697939 cites W1969395455 @default.
• W2068697939 cites W1982565816 @default.
• W2068697939 cites W1999286290 @default.
• W2068697939 cites W2025847464 @default.
• W2068697939 cites W2036653122 @default.
• W2068697939 cites W2053117040 @default.
• W2068697939 cites W2055552287 @default.
• W2068697939 cites W2068321480 @default.
• W2068697939 cites W2126348031 @default.
• W2068697939 cites W2137634002 @default.
• W2068697939 cites W2138595885 @default.
• W2068697939 cites W2159233098 @default.
• W2068697939 cites W2162313028 @default.
• W2068697939 cites W2164763924 @default.
• W2068697939 cites W2292308933 @default.
• W2068697939 cites W31674920 @default.
• W2068697939 cites W2133310936 @default.
• W2068697939 doi "https://doi.org/10.1159/000345081" @default.
• W2068697939 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23207482" @default.
• W2068697939 hasPublicationYear "2012" @default.
• W2068697939 type Work @default.
• W2068697939 sameAs 2068697939 @default.
• W2068697939 citedByCount "23" @default.
• W2068697939 countsByYear W20686979392013 @default.
• W2068697939 countsByYear W20686979392014 @default.
• W2068697939 countsByYear W20686979392015 @default.
• W2068697939 countsByYear W20686979392016 @default.
• W2068697939 countsByYear W20686979392017 @default.
• W2068697939 countsByYear W20686979392018 @default.
• W2068697939 countsByYear W20686979392019 @default.
• W2068697939 countsByYear W20686979392020 @default.
• W2068697939 countsByYear W20686979392022 @default.
• W2068697939 crossrefType "journal-article" @default.
• W2068697939 hasAuthorship W2068697939A5000920255 @default.
• W2068697939 hasAuthorship W2068697939A5006918138 @default.
• W2068697939 hasAuthorship W2068697939A5008224042 @default.
• W2068697939 hasAuthorship W2068697939A5009067298 @default.
• W2068697939 hasAuthorship W2068697939A5011252047 @default.
• W2068697939 hasAuthorship W2068697939A5014564210 @default.
• W2068697939 hasAuthorship W2068697939A5016264225 @default.
• W2068697939 hasAuthorship W2068697939A5021210152 @default.
• W2068697939 hasAuthorship W2068697939A5021310833 @default.
• W2068697939 hasAuthorship W2068697939A5021457180 @default.
• W2068697939 hasAuthorship W2068697939A5022472213 @default.
• W2068697939 hasAuthorship W2068697939A5022557432 @default.
• W2068697939 hasAuthorship W2068697939A5025237260 @default.
• W2068697939 hasAuthorship W2068697939A5025574771 @default.
• W2068697939 hasAuthorship W2068697939A5026655540 @default.
• W2068697939 hasAuthorship W2068697939A5033206744 @default.

• next